S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

RadNet Stock Forecast, Price & News

+0.15 (+0.86%)
(As of 06/29/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
306,390 shs
Average Volume
270,642 shs
Market Capitalization
$989.45 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive RDNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.

RDNT Stock Forecast (MarketRank)

Overall MarketRank

2.43 out of 5 stars

Medical Sector

178th out of 1,432 stocks

Medical Laboratories Industry

5th out of 32 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
RadNet logo

About RadNet (NASDAQ:RDNT)

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

RDNT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
$24.73 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.32 billion
Cash Flow
$3.88 per share
Book Value
$6.51 per share


Free Float
Market Cap
$989.45 million

Social Links

RadNet Frequently Asked Questions

Should I buy or sell RadNet stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RadNet stock.
View analyst ratings for RadNet
or view top-rated stocks.

What is RadNet's stock price forecast for 2022?

2 Wall Street analysts have issued 12 month price objectives for RadNet's stock. Their RDNT stock forecasts range from $39.00 to $39.00. On average, they anticipate RadNet's share price to reach $39.00 in the next year. This suggests a possible upside of 121.6% from the stock's current price.
View analysts' price targets for RadNet
or view top-rated stocks among Wall Street analysts.

How has RadNet's stock price performed in 2022?

RadNet's stock was trading at $30.11 on January 1st, 2022. Since then, RDNT stock has decreased by 41.5% and is now trading at $17.60.
View the best growth stocks for 2022 here

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for RadNet

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) posted its quarterly earnings data on Monday, May, 9th. The medical research company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.13. The medical research company had revenue of $341.80 million for the quarter, compared to the consensus estimate of $333.46 million. RadNet had a trailing twelve-month return on equity of 6.82% and a net margin of 1.36%. RadNet's revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.04 earnings per share.
View RadNet's earnings history

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.36 billion-$1.41 billion, compared to the consensus revenue estimate of $1.38 billion.

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Dr. Howard G. Berger M.D., Chairman, Pres & CEO (Age 76, Pay $4.57M)
  • Mr. Mark D. Stolper, Exec. VP & CFO (Age 51, Pay $947.22k)
  • Mr. Mital Patel, Exec. VP of Financial Planning & Analysis and Chief Admin. Officer (Age 36, Pay $937.93k)
  • Mr. Norman R. Hames, Pres & COO of Western Operations (Age 66, Pay $1.07M) (LinkedIn Profile)
  • Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 61, Pay $1.09M)
  • Ms. Christine Nayoma Gordon, Sr. VP of Operations - Northern California & Director (Age 59, Pay $397.77k)
  • Ms. Ruth Louisa Villiger-Wilson, HR Advisor & Director (Age 58, Pay $407.4k) (LinkedIn Profile)
  • Mr. Ranjan Jayanathan, Exec. VP, Chief Information Officer & GM of eRAD - Radiology Information Technology Division (Age 66)
  • Ms. Laura Foster BSRT, MPH, J.D., Sr. VP of Compliance & Regulatory Affairs
  • Mr. David Jeffrey Katz, Exec. VP, Gen. Counsel & Corp. Sec. (Age 58)

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet CEO Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among RadNet's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $17.60.

How much money does RadNet make?

RadNet (NASDAQ:RDNT) has a market capitalization of $989.45 million and generates $1.32 billion in revenue each year. The medical research company earns $24.73 million in net income (profit) each year or $0.33 on an earnings per share basis.

How many employees does RadNet have?

RadNet employs 8,973 workers across the globe.

When was RadNet founded?

RadNet was founded in 1980.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The official website for RadNet is www.radnet.com. The medical research company can be reached via phone at (310) 445-2800, via email at [email protected], or via fax at 310-445-2980.

This page (NASDAQ:RDNT) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.